Alkermes vs ImmunityBio

Alkermes (ALKS), health care, and ImmunityBio (IBRX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Alkermes is worth $7.7B on the stock market and ImmunityBio $6.6B: Alkermes is valued at 16% more. Alkermes's operating margin in its latest fiscal year was 17.2% and ImmunityBio's -226%. Over the past year Alkermes's share price has moved +59.0% and ImmunityBio's +185%.

Key facts

Alkermes market value
$7.7B
ImmunityBio market value
$6.6B
Alkermes revenue
$1.5BFY to 2025-12-31
ImmunityBio revenue
$113.3MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Alkermes vs ImmunityBio: every measure side by side
Measure Alkermes ImmunityBio
SectorHealth CareHealth Care
Country Ireland United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.7Bhigher$6.6Blower
Revenue$1.5Bhigher$113.3Mlower
Earnings$241.7Mhigher-$351.4Mlower
Employees2,050higher684lower
Total assets$2.5Bhigher$501.9Mlower
Valuation
P/E——
P/S5.2lower58.4higher
P/B——
Dividend yield—0.00%
Profitability
Operating margin17.2%higher-226%lower
Balance sheet
Net assets$1.8Bhigher-$500.5Mlower
Total liabilities$667.7Mlower$1Bhigher
Total debt——
Cash on hand$388.6Mhigher$88.3Mlower
Price change
Today-1.98%lower+4.01%higher
1 year+59.0%lower+185%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

ImmunityBio only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns ALKS

Further comparisons

Learn

Questions and answers

Which is bigger, Alkermes or ImmunityBio?

By market value, Alkermes is the larger: $7.7B against $6.6B for ImmunityBio. By revenue in its latest fiscal year, Alkermes is the larger: $1.5B against $113.3M for ImmunityBio.

Which has the higher operating margin?

Alkermes: 17.2%, against -226% for ImmunityBio. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Alkermes and ImmunityBio?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold Alkermes and 0 hold ImmunityBio.

Cite this page

Funkfolio, “Alkermes vs ImmunityBio”, data as of 17 November 2026. https://funkfolio.com/compare/alks-vs-ibrx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.